IL326448A - Bicyclic peptide ligands specific for mt1-mmp - Google Patents

Bicyclic peptide ligands specific for mt1-mmp

Info

Publication number
IL326448A
IL326448A IL326448A IL32644826A IL326448A IL 326448 A IL326448 A IL 326448A IL 326448 A IL326448 A IL 326448A IL 32644826 A IL32644826 A IL 32644826A IL 326448 A IL326448 A IL 326448A
Authority
IL
Israel
Prior art keywords
seq
referred
harg
lpp
loop
Prior art date
Application number
IL326448A
Other languages
English (en)
Hebrew (he)
Original Assignee
Bicycletx Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1820286.1A external-priority patent/GB201820286D0/en
Priority claimed from GBGB1906534.1A external-priority patent/GB201906534D0/en
Application filed by Bicycletx Ltd filed Critical Bicycletx Ltd
Publication of IL326448A publication Critical patent/IL326448A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6489—Metalloendopeptidases (3.4.24)
    • C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IL326448A 2018-12-13 2019-12-13 Bicyclic peptide ligands specific for mt1-mmp IL326448A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1820286.1A GB201820286D0 (en) 2018-12-13 2018-12-13 Bicyclic peptide ligands specific for mt1-mmp
GBGB1906534.1A GB201906534D0 (en) 2019-05-09 2019-05-09 Bicycle peptide ligands specific for MT1-MMP
PCT/GB2019/053540 WO2020120984A1 (en) 2018-12-13 2019-12-13 Bicyclic peptide ligands specific for mt1-mmp

Publications (1)

Publication Number Publication Date
IL326448A true IL326448A (en) 2026-04-01

Family

ID=68988066

Family Applications (2)

Application Number Title Priority Date Filing Date
IL326448A IL326448A (en) 2018-12-13 2019-12-13 Bicyclic peptide ligands specific for mt1-mmp
IL283873A IL283873B2 (en) 2018-12-13 2021-06-10 Bicyclic peptide ligands specific for MT1-MMP

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL283873A IL283873B2 (en) 2018-12-13 2021-06-10 Bicyclic peptide ligands specific for MT1-MMP

Country Status (12)

Country Link
US (1) US20220024982A1 (cg-RX-API-DMAC10.html)
EP (1) EP3894010A1 (cg-RX-API-DMAC10.html)
JP (2) JP2022513806A (cg-RX-API-DMAC10.html)
KR (2) KR20210123295A (cg-RX-API-DMAC10.html)
CN (1) CN113507962A (cg-RX-API-DMAC10.html)
AU (2) AU2019398516B2 (cg-RX-API-DMAC10.html)
BR (1) BR112021011340A2 (cg-RX-API-DMAC10.html)
CA (1) CA3122669A1 (cg-RX-API-DMAC10.html)
IL (2) IL326448A (cg-RX-API-DMAC10.html)
MX (1) MX2021006991A (cg-RX-API-DMAC10.html)
SG (1) SG11202106081YA (cg-RX-API-DMAC10.html)
WO (1) WO2020120984A1 (cg-RX-API-DMAC10.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ731185A (en) 2014-10-29 2024-03-22 Bicyclerd Ltd Bicyclic peptide ligands specific for mt1-mmp
EP3559018A1 (en) 2016-12-23 2019-10-30 Bicyclerd Limited Peptide derivatives having novel linkage structures
WO2019002842A1 (en) 2017-06-26 2019-01-03 Bicyclerd Limited BICYCLIC PEPTIDE LIGANDS WITH DETECTABLE FRACTIONS AND USES THEREOF
JP7670481B2 (ja) 2017-08-04 2025-04-30 バイスクルテクス・リミテッド Cd137に対して特異的な二環式ペプチドリガンド
TWI825046B (zh) 2017-12-19 2023-12-11 英商拜西可泰克斯有限公司 Epha2特用之雙環胜肽配位基
CA3091775A1 (en) 2018-02-23 2019-08-29 Bicycletx Limited Multimeric bicyclic peptide ligands
US11180531B2 (en) 2018-06-22 2021-11-23 Bicycletx Limited Bicyclic peptide ligands specific for Nectin-4
GB201820288D0 (en) * 2018-12-13 2019-01-30 Bicycle Tx Ltd Bicycle peptide ligaands specific for MT1-MMP
GB201820295D0 (en) * 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for MT1-MMP
GB201820325D0 (en) 2018-12-13 2019-01-30 Bicyclerd Ltd Bicyclic peptide ligands specific for psma
WO2020128527A1 (en) 2018-12-21 2020-06-25 Bicyclerd Limited Bicyclic peptide ligands specific for pd-l1
EP3897849A1 (en) 2018-12-21 2021-10-27 BicycleTx Limited Bicyclic peptide ligands specific for pd-l1
GB201900529D0 (en) 2019-01-15 2019-03-06 Bicycletx Ltd Bicyclic peptide ligands specific for CD38
TWI860386B (zh) 2019-07-30 2024-11-01 英商拜西可泰克斯有限公司 異質雙環肽複合物
CN116348476A (zh) 2020-08-03 2023-06-27 拜斯科技术开发有限公司 基于肽的接头
CA3206529A1 (en) * 2021-01-08 2022-07-14 Bicycletx Limited Heterotandem bicyclic peptide complexes
US12539335B2 (en) 2021-09-29 2026-02-03 Conjustar (Zhuhai) Biologics Co., Ltd. Tricyclic polypeptide conjugated drug and use thereof
WO2023088236A1 (zh) * 2021-11-16 2023-05-25 海思科医药集团股份有限公司 Mt1-mmp的双环肽配体及其缀合物

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1452868A2 (en) 2003-02-27 2004-09-01 Pepscan Systems B.V. Method for selecting a candidate drug compound
ES2428869T3 (es) 2005-01-24 2013-11-12 Pepscan Systems B.V. Compuestos de unión, compuestos inmunógenos y peptidomiméticos
JP6074574B2 (ja) * 2008-02-05 2017-02-08 バイシクル セラピューティクス リミテッド 方法及び組成物
GB0913775D0 (en) * 2009-08-06 2009-09-16 Medical Res Council Multispecific peptides
WO2013142229A1 (en) * 2012-03-19 2013-09-26 President And Fellows Of Harvard College Designing novel peptides for inducing fibronectin matrix assembly
GB201306623D0 (en) * 2013-04-11 2013-05-29 Bicycle Therapeutics Ltd Modulation of structured polypeptide specificity
NZ731185A (en) * 2014-10-29 2024-03-22 Bicyclerd Ltd Bicyclic peptide ligands specific for mt1-mmp
GB201600911D0 (en) * 2016-01-18 2016-03-02 Bicycle Therapeutics Ltd Stabilized peptide derivatives
GB201607827D0 (en) * 2016-05-04 2016-06-15 Bicycle Therapeutics Ltd Bicyclic peptide-toxin conjugates specific for MT1-MMP
MX2019007367A (es) * 2016-12-23 2020-01-27 Bicycletx Ltd Ligandos de peptido para enlace a mt1-mmp.
GB201713560D0 (en) * 2017-08-23 2017-10-04 Bicycle Therapeutics Ltd Peptide ligands for binding to Mt1-Mmp
ES2985986T3 (es) * 2017-01-06 2024-11-08 Bicyclerd Ltd Conjugado biciclo para tratar el cáncer
EP3615550A1 (en) * 2017-04-27 2020-03-04 BicycleTx Limited Bicyclic peptide ligands and uses thereof

Also Published As

Publication number Publication date
US20220024982A1 (en) 2022-01-27
WO2020120984A1 (en) 2020-06-18
SG11202106081YA (en) 2021-07-29
EP3894010A1 (en) 2021-10-20
AU2019398516B2 (en) 2025-09-04
AU2019398516A1 (en) 2021-08-05
KR20260109975A (ko) 2026-07-13
AU2025271131A1 (en) 2025-12-18
JP2024119862A (ja) 2024-09-03
JP2022513806A (ja) 2022-02-09
CA3122669A1 (en) 2020-06-18
MX2021006991A (es) 2021-10-13
IL283873A (en) 2021-07-29
IL283873B2 (en) 2026-07-01
CN113507962A (zh) 2021-10-15
BR112021011340A2 (pt) 2021-09-08
KR20210123295A (ko) 2021-10-13
IL283873B1 (en) 2026-03-01

Similar Documents

Publication Publication Date Title
IL283873B1 (en) Bicyclic peptide ligands specific for MT1-MMP
ZA202100442B (en) Bicyclic peptide ligands specific for nectin-4
GB201820295D0 (en) Bicyclic peptide ligands specific for MT1-MMP
IL276803A (en) Peptide ligands in multimeric cycles
IL283874A (en) Bicyclic peptide ligands specific for mt1-mmp
GB201820316D0 (en) Bicyclic peptide ligands specific for IL-17
GB201820320D0 (en) Bicyclic peptide ligands specific for FAPalpha
GB201820286D0 (en) Bicyclic peptide ligands specific for mt1-mmp
GB201607535D0 (en) Peptides
HK40060302A (en) Bicyclic peptide ligands specific for mt1-mmp
HK40060303A (en) Bicyclic peptide ligands specific for mt1-mmp
GB201818499D0 (en) Bicyclic peptide ligands specific for nectin-4
GB201815684D0 (en) Bicyclic peptide ligands specific for nectin-4
GB201918495D0 (en) Bicyclic peptide ligands specific for il-46
GB201820321D0 (en) Bicyclic peptide ligands specific for MMP9
GB201904632D0 (en) Bicyclic peptide ligands specific for nectin-4
HK40050152A (en) Bicyclic peptide ligands specific for nectin-4
GB201820956D0 (en) Bicyclic peptide ligands specific for pd-l1
GB201720934D0 (en) Bicyclic peptide ligands specific for FAPalpha
GB201820322D0 (en) Bicyclic peptide ligands specific for TGFbeta
GB201820315D0 (en) Bicyclic peptide ligands specific for IL-9
GB201712693D0 (en) Bicyclic peptide ligands specific for nectin-4
GB201820313D0 (en) Bicyclic peptide ligands specific for KLK5
GB201818158D0 (en) Multimeric bicyclic peptide ligands
GB201820318D0 (en) Bicyclic peptide ligands specific for cathepsin G